Hepatitis B screening: Difference between revisions
Joao Silva (talk | contribs) No edit summary |
Joao Silva (talk | contribs) No edit summary |
||
| Line 8: | Line 8: | ||
===Large-scale screening for HBV infection=== | ===Large-scale screening for HBV infection=== | ||
Diagnosis of hepatitis is made by biochemical assessment of liver function. Initial laboratory evaluation should include: | Diagnosis of hepatitis is made by biochemical assessment of liver function. Initial laboratory evaluation should include:<ref name=WHO>{{cite web | title = Hepatitis B | url = http://www.who.int/csr/disease/hepatitis/HepatitisB_whocdscsrlyo2002_2.pdf }}</ref><ref>{{cite book | last = Fields | first = Bernard | title = Fields virology | publisher = Wolters Kluwer Health/Lippincott Williams & Wilkins | location = Philadelphia | year = 2007 | isbn = 0781760607 }}</ref> | ||
* Total and direct [[bilirubin]] | |||
* [[ALT]] | |||
* [[AST]] | |||
* [[Alkaline phosphatase]] | |||
* [[Prothrombin time]] | |||
* [[Total protein]] | |||
* [[Albumin]] | |||
* [[Globulin]] | |||
* [[Complete blood count]] | |||
* [[Coagulation]] studies | |||
Revision as of 19:50, 29 July 2014
|
Hepatitis B |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hepatitis B screening On the Web |
|
American Roentgen Ray Society Images of Hepatitis B screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Overview
Screening
Large-scale screening for HBV infection
Diagnosis of hepatitis is made by biochemical assessment of liver function. Initial laboratory evaluation should include:[1][2]
- Total and direct bilirubin
- ALT
- AST
- Alkaline phosphatase
- Prothrombin time
- Total protein
- Albumin
- Globulin
- Complete blood count
- Coagulation studies
Recommendations for Persons Who Should Be Tested for HBV Infection: AASLD Practice Guidelines 2009[3]
| “ | The following groups should be tested for HBV
infection:
|
” |
Recommendations for HCC Screening: AASLD Practice Guidelines 2009[3]
| “ |
1. HBV carriers at high risk for HCC such as Asian men over 40 years and Asian women over 50 years of age, persons with cirrhosis, persons with a family history of HCC, Africans over 20 years of age, and any carrier over 40 years with persistent or intermittent ALT elevation and/or high HBV DNA level >2,000 IU/mL should be screened with US examination every 6-12 months. (Grade II-2) 2. For HBV carriers at high risk for HCC who are living in areas where US is not readily available, periodic screening with AFP should be considered. (Grade II-2) |
” |
References
- ↑ "Hepatitis B" (PDF).
- ↑ Fields, Bernard (2007). Fields virology. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. ISBN 0781760607.
- ↑ 3.0 3.1 Lok AS, McMahon BJ (2004). "[AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines]" (PDF). Romanian Journal of Gastroenterology. 13 (2): 150–4. PMID 15229781. Retrieved 2012-02-10. Unknown parameter
|month=ignored (help)